Generic drug
Pimecrolimus price, strengths & recalls
Pharmacies pay $99.56 for 30 g of Pimecrolimus 10 mg/mL cream this week. 4 manufacturers make it. It has 1 recall on record, none ongoing. Its official label last changed on May 21, 2026.
Generic- Fair cash price
- $124.99
- Strengths
- 1
- Makers
- 4
- Updated
- Nov 11
Pimecrolimus price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 10 mg/mL cream | $3.32 | $99.56 / 30 g |
Supply status: shortages & recalls
Recalls
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Pimecrolimus
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use PIMECROLIMUS safely and effectively. See full prescribing information for PIMECROLIMUS.PIMECROLIMUS cream, for topical useInitial U.S. Approval: 2001
WARNING: LONG-TERM SAFETY OF TOPICAL CALCINEURIN INHIBITORS HAS NOT BEEN ESTABLISHED
Although a causal relationship has not been established, rare cases of malignancy (e.g., skin and lymphoma) have been reported in patients treated with topical calcineurin inhibitors, including Pimecrolimus Cream, 1%. [see Warnings and Precautions (5.1)].
Therefore:
•
Continuous long-term use of topical calcineurin inhibitors, including Pimecrolimus Cream, 1%, in any age group should be avoided and application limited to areas of involvement with atopic dermatitis [see Dosage and Administration (2), Warnings and Precautions (5.1)].
•
Pimecrolimus Cream, 1% is not indicated for use in children less than 2 years of age [see Warnings and Precautions (5.1), Use in Specific Populations (8.4)].
WARNING: LONG-TERM SAFETY OF TOPICAL CALCINEURIN INHIBITORS HAS NOT BEEN ESTABLISHED
See full prescribing information for complete boxed warning.
Although a causal relationship has not been established, rare cases of malignancy (e.g., skin and lymphoma) have been reported in patients treated with topical calcineurin inhibitors, including Pimecrolimus Cream, 1%. (5.1)
Therefore:
•
Continuous long-term use of topical calcineurin inhibitors, including Pimecrolimus Cream, 1%, in any age group should be avoided and application limited to areas of involvement with atopic dermatitis. (2, 5.1)
•
Pimecrolimus Cream, 1% is not indicated for use in children less than 2 years of age. (1, 5.1, 8.4)
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA021302 · Bausch
- First approved
- December 13, 2001 (25 years ago)
- Latest approved change
- June 9, 2016
- Approved label
- PDF, Apr 1, 2014
- Generic makers
- 2 approved generic applications on the market
Pimecrolimus questions
How much does pimecrolimus cost without insurance?
Pharmacies pay about $99.56 for 30 g of pimecrolimus 10 mg/mL cream ($3.32 per gram). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $124.99. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is pimecrolimus in shortage?
No shortage is reported for pimecrolimus right now. We check the national shortage list every day.
Has pimecrolimus been recalled?
1 recall on record, none ongoing. Recalls name specific lots - check yours.
When did the pimecrolimus label last change?
The official label was last updated on May 21, 2026 (version 4). See what changed.
Talk about pimecrolimus
No comments yet. Questions, tips, what worked for you - start the conversation.